APA (7th ed.) Citation

Tibalinda, P., Sempombe, J., Shedafa, R., Masota, N., Pius, D., Temu, M., & Kaale, E. (2016). Formulation development and optimization of Lamivudine 300 mg and Tenofovir Disoproxil Fumarate (TDF) 300 mg FDC tablets by D-optimal mixture design. Elsevier.

Chicago Style (17th ed.) Citation

Tibalinda, Prosper, Joseph Sempombe, Raphael Shedafa, Nelson Masota, Dickson Pius, Mary Temu, and Eliangiringa Kaale. Formulation Development and Optimization of Lamivudine 300 Mg and Tenofovir Disoproxil Fumarate (TDF) 300 Mg FDC Tablets by D-optimal Mixture Design. Elsevier, 2016.

MLA (8th ed.) Citation

Tibalinda, Prosper, et al. Formulation Development and Optimization of Lamivudine 300 Mg and Tenofovir Disoproxil Fumarate (TDF) 300 Mg FDC Tablets by D-optimal Mixture Design. Elsevier, 2016.